These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 27395005)

  • 1. Chronic healthcare expenditure in survivors of sepsis in the intensive care unit.
    Koster-Brouwer ME; van de Groep K; Pasma W; Smeets HM; Slooter AJC; de Lange DW; van Dijk D; van der Poll T; Bonten MJM; Cremer OL;
    Intensive Care Med; 2016 Oct; 42(10):1641-1642. PubMed ID: 27395005
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cost differences in the treatment of severe sepsis between survivors and non-survivors on the first day of intensive care admission].
    Csomós A; Szentkereszty Z; Fülesdi B
    Orv Hetil; 2007 Sep; 148(39):1851-6. PubMed ID: 17890173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost evaluation of patients with severe sepsis in intensive care units.
    Piacevoli Q; Palazzo F; Azzeri F
    Minerva Anestesiol; 2004 Jun; 70(6):453-71. PubMed ID: 15235553
    [No Abstract]   [Full Text] [Related]  

  • 4. Economics and outcome in the intensive care unit.
    Pittoni GM; Scatto A
    Curr Opin Anaesthesiol; 2009 Apr; 22(2):232-6. PubMed ID: 19390250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The economic burden of sepsis in Austria.
    Schmid A; Schneider H
    Wien Klin Wochenschr; 2002 Dec; 114(23-24):1023-4; author reply 1024. PubMed ID: 12635473
    [No Abstract]   [Full Text] [Related]  

  • 6. The costs of septic syndromes in the intensive care unit and influence of hospital-acquired sepsis.
    Brun-Buisson C; Roudot-Thoraval F; Girou E; Grenier-Sennelier C; Durand-Zaleski I
    Intensive Care Med; 2003 Sep; 29(9):1464-71. PubMed ID: 12856120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of drotrecogin alfa (activated).
    Tsitanidis J
    Crit Care Med; 2003 Sep; 31(9):2414-5; author reply 2415. PubMed ID: 14501983
    [No Abstract]   [Full Text] [Related]  

  • 8. [Calculation of costs per inpatient day in an intensive care unit].
    Alvear V S; Canteros J; Rodríguez P
    Rev Med Chil; 2010 May; 138(5):558-66. PubMed ID: 20668810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical imperative versus economic consequence: exploring the cost burden and opportunities in the care of patients with sepsis.
    Merritt CL
    Nurs Adm Q; 2011; 35(1):61-7. PubMed ID: 21157265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The incidence and cost of severe sepsis in intensive care units].
    Csomós A; Hoffer G; Fülesdi B; Ludwig E
    Orv Hetil; 2005 Jul; 146(29):1543-7. PubMed ID: 16136776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drotrecogin alfa's impact on intensive care workload in real life practice: a propensity score approach.
    Riou França L; Payet S; Le Lay K; Launois R
    Value Health; 2008 Dec; 11(7):1051-60. PubMed ID: 18494757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacist on intensive care unit saves lives and reduces costs.
    Knibbe CA; Tjoeng MM
    Crit Care Med; 2008 Dec; 36(12):3269-70. PubMed ID: 19020439
    [No Abstract]   [Full Text] [Related]  

  • 13. Economic implications of an evidence-based sepsis protocol: can we improve outcomes and lower costs?
    Shorr AF; Micek ST; Jackson WL; Kollef MH
    Crit Care Med; 2007 May; 35(5):1257-62. PubMed ID: 17414080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The attributable mortality and costs of primary nosocomial bloodstream infections in the intensive care unit.
    Digiovine B; Chenoweth C; Watts C; Higgins M
    Am J Respir Crit Care Med; 1999 Sep; 160(3):976-81. PubMed ID: 10471627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A microcosting study of intensive care unit stay in the Netherlands.
    Tan SS; Hakkaart-van Roijen L; Al MJ; Bouwmans CA; Hoogendoorn ME; Spronk PE; Bakker J
    J Intensive Care Med; 2008; 23(4):250-7. PubMed ID: 18508839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Can we afford the costs of progress in intensive care medicine? A plea for a candid debate].
    Boldt J
    Dtsch Med Wochenschr; 2004 Jan; 129(1-2):36-40. PubMed ID: 14703580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Untangling the healthcare use patterns of severe sepsis survivors.
    Wunsch H
    Am J Respir Crit Care Med; 2014 Jul; 190(1):7-8. PubMed ID: 24983217
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluating the clinical and financial impact of severe sepsis with Medicare or other administrative hospital data.
    Ernst FR; Malatestinic WN; Linde-Zwirble WT
    Am J Health Syst Pharm; 2006 Mar; 63(6):575-81. PubMed ID: 16522894
    [No Abstract]   [Full Text] [Related]  

  • 19. Growth of intensive care unit resource use and its estimated cost in Medicare.
    Milbrandt EB; Kersten A; Rahim MT; Dremsizov TT; Clermont G; Cooper LM; Angus DC; Linde-Zwirble WT
    Crit Care Med; 2008 Sep; 36(9):2504-10. PubMed ID: 18679127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Call to tackle sepsis.
    Bosch X
    Lancet Infect Dis; 2002 Nov; 2(11):649. PubMed ID: 12409032
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.